文献速递心外重症与机械循环支持

HeartMate II 左心室辅助装置植入后心脏移植的最佳时机

Optimal Timing of Heart Transplant After HeartMate II Left Ventricular Assist Device Implantation.
PubMed 文献 · Ann Thorac Surg · 2017-06-24

以 LVAD 生存与移植生存的乘积作为最佳移植时机指标。植入后 9 个月内移植者 3 年生存无变化,支持时间超过 9 个月后生存下降,术前合并症与术后并发症影响生存。

要点

  • LVAD 植入后 9 个月内行心脏移植,3 年生存未见下降
  • 支持时间超过 9 个月后,生存随支持时间延长而下降
  • 术前合并症多者支持时间越长生存越差,应在并发症前移植

核心结论

  • HeartMate II 支持患者的生存受术前合并症与术后并发症影响,应在并发症发生前完成移植以优化生存。

研究设计与样本

  • 最佳移植时机定义为 LVAD 支持生存与移植生存的乘积。

主要发现

  • 植入后 9 个月内行心脏移植者,LVAD 植入后与心脏移植后 3 年生存均无变化;支持时间超过 9 个月后生存下降。
  • LVAD 支持期间死亡的术前危险因素包括既往瓣膜手术、既往冠状动脉旁路移植、低白蛋白、低肾小球滤过率、较高平均动脉压、高血压及较早植入日期。
  • 无上述危险因素者,移植在 3 个月内进行时生存最低,随支持时间延长相对稳定;危险因素多者支持时间越长生存越差。
  • LVAD 支持期间装置再植入、颅内出血及植入后透析与生存下降相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimal timing of heart transplantation in patients supported with second-generation left ventricular assist devices (LVADs) is unknown. Despite this, patients with LVADs continue to receive priority on the heart transplant waiting list. Our objective was to determine the optimal timing of transplantation for patients bridged with continuous-flow LVADs. METHODS: A total of 301 HeartMate II LVADs (Thoratec Corp, Pleasanton, CA) were implanted in 285 patients from October 2004 to June 2013, and 86 patients underwent transplantation through the end of follow-up. Optimal transplantation timing was the product of surviving on LVAD support and surviving transplant. RESULTS: Three-year survival after both HeartMate II implantation and heart transplantation was unchanged when transplantation occurred within 9 months of implantation. Survival decreased as the duration of support exceeded this. Preoperative risk factors for death on HeartMate II support were prior valve operation, prior coronary artery bypass grafting, low albumin, low glomerular filtration rate, higher mean arterial pressure, hypertension, and earlier date of implant. Survival for patients without these risk factors was lowest when transplant was performed within 3 months but was relatively constant with increased duration of support. Longer duration of support was associated with poorer survival for patients with many of these risk factors. Device reimplantation, intracranial hemorrhage, and postimplant dialysis during HeartMate II support were associated with decreased survival. CONCLUSIONS: Survival of patients supported by the HeartMate II is affected by preoperative comorbidities and postoperative complications. Transplantation before complications is imperative in optimizing survival.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Steffen RJ, Blackstone EH, Smedira NG, et al. Optimal Timing of Heart Transplant After HeartMate II Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2017. PMID: 28651783. doi:10.1016/j.athoracsur.2017.03.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。